BioStem Reports Q3 Revenue of $7.6 Million, Raises 2026 Guidance
BioStem reported a GAAP net loss of $11.4 million for the quarter ended September 30, 2026. It raised full-year revenue guidance to $28 million–$29 million from $26 million–$29 million.
BioStem Technologies, Inc. announced its financial results for the third quarter ended September 30, 2026, reporting net revenue of $7.6 million and a GAAP net loss of $11.4 million. The company achieved sequential growth in hospital revenue, which reached $6.8 million, and noted a 14% increase in customers purchasing two or more product lines compared to the second quarter of 2026. Management raised its full-year 2026 revenue guidance to a range of $28 million to $29 million, up from the previous outlook of $26 million to $29 million.
Additionally, the company reported that in-house production of its Neox and Clarix product lines is on track to commence in the first half of 2027. The company also disclosed that its CEO and COO exercised options generating approximately $1.0 million in gross proceeds subsequent to the quarter.